Nevro Corp. (NYSE:NVRO) Given Average Recommendation of “Hold” by Analysts

Nevro Corp. (NYSE:NVRO) has been assigned an average rating of “Hold” from the thirteen analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $21.23.

A number of equities research analysts have issued reports on NVRO shares. Royal Bank of Canada reduced their price objective on shares of Nevro from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Monday. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $23.00 price objective on shares of Nevro in a research report on Thursday, December 21st. Oppenheimer downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 22nd. Wells Fargo & Company reduced their price objective on shares of Nevro from $17.00 to $14.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. Finally, Mizuho reduced their target price on shares of Nevro from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 11th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NVRO. Quarry LP boosted its holdings in Nevro by 174.3% in the 2nd quarter. Quarry LP now owns 1,012 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 643 shares during the period. UBS Group AG lifted its stake in Nevro by 206.3% in the 4th quarter. UBS Group AG now owns 1,219 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 821 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Nevro by 26.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,162 shares of the medical equipment provider’s stock worth $61,000 after purchasing an additional 668 shares in the last quarter. Assetmark Inc. lifted its stake in Nevro by 30.4% in the 4th quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 730 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC purchased a new stake in Nevro in the 3rd quarter worth approximately $132,000. 95.52% of the stock is owned by institutional investors.

Nevro Trading Up 1.6 %

NVRO opened at $12.69 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.37 and a quick ratio of 4.94. Nevro has a fifty-two week low of $12.23 and a fifty-two week high of $39.67. The firm has a market capitalization of $461.92 million, a PE ratio of -4.94 and a beta of 0.89. The company’s 50-day moving average is $14.82 and its 200 day moving average is $16.94.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Wednesday, February 21st. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.35. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The business had revenue of $116.18 million during the quarter, compared to the consensus estimate of $115.93 million. As a group, research analysts predict that Nevro will post -2.54 earnings per share for the current fiscal year.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.